ofloxacin and epirubicin

ofloxacin has been researched along with epirubicin in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (16.67)	18.2507
2000's	3 (50.00)	29.6817
2010's	1 (16.67)	24.3611
2020's	1 (16.67)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bertini, M; Botto, B; Cinieri, S; Ciotti, R; Di Nota, A; Di Vito, F; Freilone, R; Levis, A; Orsucci, L; Pini, M; Resegotti, L; Rota-Scalabrini, D; Todeschini, G; Vitolo, U	1
Duarte, MP; Galhano, J; Marcelo, GA; Oliveira, E	1

Reviews

1 review(s) available for ofloxacin and epirubicin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for ofloxacin and epirubicin

Article	Year
The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leukemia & lymphoma, 1996, Volume: 22, Issue:5-6 Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Bleomycin; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Ketoconazole; Lymphoma, Non-Hodgkin; Male; Mycoses; Neoplasm Staging; Ofloxacin; Prednisone; Prognosis; Prospective Studies; Recombinant Proteins; Survival Rate; Vinblastine	1996

Article

Year

The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.

Leukemia & lymphoma, 1996, Volume: 22, Issue:5-6

Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Bleomycin; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Ketoconazole; Lymphoma, Non-Hodgkin; Male; Mycoses; Neoplasm Staging; Ofloxacin; Prednisone; Prognosis; Prospective Studies; Recombinant Proteins; Survival Rate; Vinblastine

1996

Other Studies

4 other study(ies) available for ofloxacin and epirubicin

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Ofloxacin@Doxorubicin-Epirubicin functionalized MCM-41 mesoporous silica-based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections. Bioorganic chemistry, 2022, Volume: 118 Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Bacterial Infections; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Drug Delivery Systems; Enterococcus faecalis; Epirubicin; Escherichia coli; Microbial Sensitivity Tests; Molecular Structure; Nanoparticles; Ofloxacin; Particle Size; Porosity; Pseudomonas aeruginosa; Silicon Dioxide; Staphylococcus aureus; Structure-Activity Relationship; Surface Properties	2022